Private equity does not pursue healthcare acquisitions at random. It pursues them according to a precise economic logic: buy relationships and market presence at a premium today, because building the same presence organically would take years. That logic holds only as long as the market has room to fill. Once a conglomerate has established meaningful density in every major geography, the strategic rationale for paying acquisition premiums evaporates — and with it, the valuation multiples that define what independent practice owners can expect at the closing table. This whitepaper examines that transition, traces it through multiple healthcare verticals, and explains why the timing of your transaction matters more than most sellers appreciate.
Why Buyers Pay Premiums for Healthcare Acquisitions — And Why That Changes
Healthcare services are not commodity businesses. A patient's relationship with a physical therapist, dentist, or ophthalmologist is built on trust, proximity, and clinical reputation — assets that take years to cultivate and cannot be replicated from a spreadsheet. When a private equity platform enters a new market, it faces a fundamental choice: acquire that trust by purchasing an established practice, or build from scratch through a de novo location.
In the early phases of a roll-up, acquisition is almost always the superior strategy. An established practice brings an existing patient panel, trained staff, referral relationships with local physicians and hospitals, community brand recognition, and — critically — revenue on day one. A de novo, by contrast, requires 12–24 months of investment before a location reaches breakeven, with no guarantee of capturing the same patient relationships the acquired practice already owns. The math strongly favors paying a premium to acquire those assets rather than rebuilding them.
The platform investor's willingness to pay that premium is not irrational. It is an explicit calculation: the cost of accelerated acquisition — even at a significant EBITDA premium — is still cheaper than the time, capital, and risk of organic entry in a market where clinical reputation determines patient volume. This is why the earliest sellers in a consolidation cycle typically achieve the highest multiples. They are not simply selling a business — they are selling a strategic foothold.
🏥
Healthcare Is Relationship Capital — And Buyers Know It
In most industries, a new competitor can enter a market by opening a location and marketing aggressively. In healthcare, referral networks, community reputation, and patient relationships are the product. These cannot be purchased at a hardware store. They must either be acquired — or rebuilt from zero, at considerable time and cost. This is the structural reason healthcare M&A commands premium multiples during active consolidation phases.
The Three Phases of Healthcare Consolidation
Every major PE-backed healthcare roll-up follows a predictable arc. Understanding where your specialty sits on that arc is the single most important variable in determining your achievable valuation today.
01
Expansion Phase
Aggressive Acquisition
PE platforms compete intensely for established practices to build geographic density quickly. Buyers pay top-of-market multiples because each acquisition delivers relationships, staff, and revenue that a de novo cannot replicate for years.
High M&A Volume
Peak Multiples
Multiple Buyers
02
Transition Phase
Selective Consolidation
Major geographies are covered. Platforms become more selective, favoring practices in white space markets or those with unique scale. M&A activity continues but competition for any single practice begins to thin. Multiples begin to moderate.
Selective Deals
Moderate Volume
Fewer Bidders
03
Saturation Phase
Organic Growth Priority
The platform has a presence in every major market. De novo expansion becomes cheaper than acquisition. Acquirer appetite falls, competition for practices diminishes, and the market-clearing multiple compresses — often by several turns of EBITDA.
Low M&A Volume
Compressed Multiples
De Novo Focus
Urgent acquisition need — pay the premium
→
Gap-filling — negotiate harder
→
No urgency — de novo is cheaper
Consolidation Saturation Across Healthcare Verticals
The pattern below is not theoretical. It has played out, in detail, across virtually every major healthcare services category that private equity has systematically entered. The following case studies document the expansion, saturation, and valuation consequences across four verticals — each offering a direct precedent for what is now unfolding in physical therapy.
Expansion Phase
From the 1990s through the early 2010s, CVS, Walgreens, and Rite Aid competed relentlessly to blanket every meaningful U.S. market with retail pharmacy locations. Their strategic logic was explicit: neighborhood pharmacist relationships are sticky, and it is far faster to buy an existing community presence than to build one. At peak expansion, the chains collectively operated over 25,000 U.S. locations. Walgreens' market capitalization exceeded $100 billion at its height in 2015, reflecting investor confidence in continued geographic expansion.
Saturation & Aftermath
By the mid-2010s, the chains had achieved near-total geographic coverage. With no meaningful white space remaining, the acquisition rationale evaporated. CVS announced closure of roughly 900 stores between 2022 and 2024. Walgreens disclosed that approximately 25% of its store footprint was unprofitable and announced plans to close 1,200 locations. Rite Aid, unable to compete at scale, filed for bankruptcy and closed all remaining locations by late 2025. Walgreens' market value had collapsed from over $100 billion to below $8 billion by 2024, ultimately taken private by Sycamore Partners for $10 billion — a fraction of its peak.
$100B+
Walgreens peak
market cap (2015)
<$8B
Walgreens value
by 2024 (–92%)
~3,000+
Combined CVS &
Walgreens closures
100%
Rite Aid stores
closed by Oct. 2025
Expansion Phase
Dental was one of private equity's most active healthcare targets throughout the 2010s and into the early 2020s. The dental market's fragmentation — tens of thousands of independent practices, each with deeply local patient relationships — made it a natural roll-up target. DSO platforms paid top-of-market premiums for well-run practices during the competitive expansion phase, with the 2021 market peak driving multiples to their highest levels as low-cost capital fueled an acquisition arms race. Dental saw more private equity deal activity than any other healthcare services subsector in 2024, with over 161 tracked deals.
Saturation Signal & Multiple Shift
By 2023–2024, most major PE firms already operated dental platforms, and the number of new entrants willing to pay entry premiums declined materially. With platforms in place, the focus shifted from buying new markets to acquiring smaller add-ons cost-effectively and pursuing de novo growth. Average multiples moderated materially from their 2021 peak. More telling: Sonrava Health (Western Dental), a large DSO with over 500 affiliated practices, underwent a distressed debt exchange in 2024 — a direct consequence of aggressive expansion and leverage in a market where the acquisition premium had already normalized.
161
PE dental deals
tracked in 2024
500+
Sonrava practices
at restructuring
Expansion Phase
Dermatology consolidation began in earnest roughly a decade ago and accelerated significantly through 2022. PE platforms competed aggressively to acquire established dermatology practices in underserved markets, paying top-quartile multiples for the community presence and physician relationships that take years to build organically. At the peak of the expansion cycle, platform-quality dermatology practices were achieving top-of-market EBITDA multiples, reflecting intense buyer competition and the strategic premium for market entry.
Saturation Signal — Platform-on-Platform Mergers
A telling sign of saturation in dermatology emerged clearly by 2022–2023: rather than competing for independent practices, platforms began merging with each other. QualDerm merged with Pinnacle Dermatology. Platinum Dermatology combined with West Dermatology. Waters Edge merged with Riverchase. When platforms stop buying independents and start consolidating among themselves, it signals that the available acquisition inventory of genuinely white space practices has been exhausted. More than 35 PE-backed dermatology platforms now operate nationally — with buyers increasingly shifting emphasis to de novo expansion in secondary markets where acquisition multiples stretch further precisely because independent competition is limited.
35+
PE-backed derm
platforms nationally
4
Major platform-on-
platform mergers (2022–24)
Expansion Phase
Ophthalmology became one of private equity's most competitive roll-up targets in the late 2010s. Established eye care practices carry deep patient loyalty and specialist referral networks that are genuinely difficult to replicate. At peak acquisition velocity, ophthalmology platforms were trading at top-of-market EBITDA multiples — a premium documented in EyeSouth Partners' sale to Olympus Partners, described by PE Hub as a "culmination of a five-year buy-and-build strategy." The specialty's surgical revenue concentration (cataract and refractive procedures) and recurring patient base made it a natural target for acquirers who understood the relationship capital embedded in a community ophthalmology practice.
Exit Cycle & Recalibration
Ophthalmology and gastroenterology platforms topped $2–4 billion in PE exit valuations in late 2024, representing the culmination of aggressive build-out cycles that began earlier in the decade. As those platforms come back to market, the conversation has shifted from "how do we acquire the next practice" to "how do we integrate what we own and grow organically." McKesson's $900 million acquisition of PRISM Vision Group in H1 2025 reflects consolidation at the platform level — a strategic buyer absorbing an already-consolidated network rather than competing for independent practices.
$2–4B
Ophthalmology/GI
platform exits (2024)
$900M
McKesson acquisition
of PRISM Vision (2025)
Platform
M&A now between
platforms, not independents
How Consolidation Phase Affects Practice Valuation Across Specialties
The following table maps each major healthcare services vertical to its current consolidation phase and the key saturation signals that define where each specialty stands in the cycle. The contrast between early-cycle and late-cycle specialties translates directly into millions of dollars in net proceeds on practices of comparable size.
| Specialty |
Consolidation Phase |
Key Saturation Signal |
| Retail Pharmacy |
Post-Saturation |
Major chains closing thousands of locations; Rite Aid fully liquidated |
| Dental (DSO) |
Late / Saturating |
Fewer new PE entrants; platform-on-platform consolidation; DSO distress events |
| Dermatology |
Late / Saturating |
35+ national platforms; major platform mergers; de novo emphasis growing |
| Ophthalmology |
Transitional |
Large PE exits completed; McKesson-scale strategic buyers absorbing platforms |
| Gastroenterology |
Transitional |
Consolidation maturing; major platforms approaching secondary exit |
| Physical Therapy |
Transitional |
Platform-on-platform acquisitions underway; major sponsors (PT Solutions, Confluent) holding exits; ATI failed IPO attempt |
| ENT / Allergy |
Early / Active |
Relatively new area for PE; high demand; significant consolidation opportunity |
| Behavioral Health |
Early / Active |
Fragmented market; strong demographic tailwinds; active platform-building |
| Consolidation Phase: Active vs. Saturated Specialty |
Timing Is a Financial Decision |
🚪
PT's Exit Signal: Sponsors Trying to Leave — and Finding It Difficult
When PE sponsors who built large PT platforms attempt to exit — and cannot — it is one of the most telling valuation signals in the market. PT Solutions and Confluent Health both reached the point where their sponsors sought exits, and both ultimately held. The market did not offer a clearing price that met sponsor expectations, so they stayed. ATI Physical Therapy pursued an exit via IPO — a route that bypasses the need for a single strategic acquirer — and that process also failed to produce the outcome sponsors sought. These are not isolated events. They reflect a market in which the largest PT platforms are priced above what buyers are willing to pay at scale, while independent practices — offered individually in a competitive process — still clear at premiums. The window between those two conditions is where independent PT owners hold their maximum leverage.
What Consolidation Saturation Means for Physical Therapy Practice Owners
Physical therapy is currently in an active consolidation phase — but the saturation signal that in other verticals was a future warning has already arrived in PT. Platform-on-platform acquisitions have begun. Results Physical Therapy was acquired by a larger platform. Pivot Physical Therapy was acquired. Access Physical Therapy was acquired. Sport and Spine Rehab was acquired. Motion Physical Therapy was acquired. These were not independent practices being folded into a roll-up — they were themselves PE-backed platforms with dozens or hundreds of locations. When platforms begin acquiring other platforms, it is the same signal that appeared in dermatology in 2022 and dental in 2023: the inventory of genuinely independent, white space practices is contracting, and consolidators are turning to each other to keep growing.
A second signal reinforces this picture: PE sponsors who built the largest PT platforms have tried to exit — and found the market unwilling to meet their price. PT Solutions and Confluent Health both reached the point where sponsor exits were pursued, and both ultimately held rather than accept a below-expectation clearing price. ATI Physical Therapy attempted an exit via IPO, a route typically taken when a direct sale does not produce adequate valuation, and that process also fell short. This pattern — large platforms unable to exit cleanly — tells independent owners something important: buyer appetite at the high end of the market is constrained. Buyers who cannot absorb a $1–2 billion platform may still compete aggressively for a well-run independent practice at $10–20 million. That gap in buyer behavior is precisely where a competitive sale process creates disproportionate value.
PE-backed platforms are still competing for well-positioned independent PT practices, and relationship capital still commands a premium over de novo build-outs. But the window is compressing. The specialties that sellers transacted in just before this signal emerged — when buyer competition was at its most intense — achieved materially better outcomes than those who waited until the cycle matured.
The saturation signal in PT is not coming. It is here. Fewer competing offers per practice, buyers increasingly selective about geography, and platforms now consolidating with each other rather than exclusively hunting independents — these are the conditions that precede multiple compression in every vertical that came before PT.
Waiting for "The Right Time"
Selling Into a Saturating Market
- Fewer PE platforms competing for your practice
- Buyers prioritize de novo over acquisitions in covered markets
- Multiple compression — 3–5 turns of EBITDA lost
- Reduced leverage in deal negotiations
- Risk of operating in a market where larger competitors build de novos nearby
- Platform consolidations mean fewer independent buyers and thinner bidder pools
vs.
Transacting During Active Consolidation
Selling Into Competitive Buyer Demand
- Multiple PE platforms competing — driving premium pricing
- Buyers paying for relationship capital and market entry, not just EBITDA
- Top-of-market multiples achieved through a competitive process
- Negotiating leverage across deal terms, not just price
- Rollover equity positioned for outsized second-bite returns
- Largest bidder pool — maximum competitive tension at every stage
📐
On a $1.5M EBITDA practice: the difference between a top-of-market multiple (active consolidation) and a compressed multiple (post-saturation) can represent millions of dollars in net proceeds — before accounting for rollover equity upside. That gap is not a negotiating rounding error. It is a generational wealth event.
The Saturation Signals — And Why PT Owners Should Act on Them Now
The consolidation cycle produces observable signals that precede multiple compression. In physical therapy, the first and most consequential signal — platform-on-platform acquisitions — has already appeared. The remaining indicators below are what to watch as the cycle continues to mature. Independent PT owners who recognize these signals early retain the most negotiating leverage.
!
Signal #1 Has Already Triggered in PT — Platform-on-Platform Acquisitions Are Underway
In dermatology and dental, platform-on-platform mergers were the clearest leading indicator that the independent practice acquisition phase was ending. That same signal has now materialized in physical therapy. Results Physical Therapy, Pivot Physical Therapy, Access Physical Therapy, Sport and Spine Rehab, and Motion Physical Therapy — all PE-backed platforms in their own right — have each been acquired by larger consolidators. This is not the sign of a market still in early build-out. It is the sign of a market whose major players are running out of independent practices to buy at scale, and are instead turning to each other. Independent PT owners who transact now still have the benefit of competing buyer demand. Those who wait may find that the platforms bidding today are fewer, larger, and less motivated to pay the premiums that a competitive, white space acquisition justified.
2
Declining Buyer Competition per Deal
During active consolidation, a well-positioned practice should receive multiple LOIs. When the number of competing offers drops materially — particularly in non-rural markets — buyers are signaling that geographic urgency has faded.
3
De Novo Expansion Becomes the Growth Strategy of Choice
When major PT consolidators publicly prioritize de novo clinic openings over acquisitions, it signals that organic build-out has become more economical than paying acquisition premiums. Ivy Rehab and Physical Rehabilitation Network (PRN) are among the PT platforms that have leaned into de novo expansion as a primary growth vehicle — a direct indication that, in the markets they already cover, building from scratch is cheaper than buying an established practice. When the largest platforms in a specialty shift capital from acquisitions to de novos, the pool of motivated acquirers paying full premiums shrinks accordingly.
4
PE Sponsors Seek Exits — and Struggle to Find Them
When the sponsors who built the largest PT platforms attempt to exit and cannot achieve their target valuation, it signals that the high end of the market has become price-constrained. PT Solutions and Confluent Health both pursued exits and held when the market did not clear at acceptable prices. ATI Physical Therapy pursued an IPO — a route taken specifically when a direct sale at scale is not viable — and that process did not produce the exit sponsors sought. Sponsors who cannot exit do not stop acquiring altogether, but they do become more cost-conscious acquirers. The premium-paying urgency of the build-out phase gives way to financial discipline, and that shift compresses multiples for independent sellers.
5
Platform Geography Overlaps in Major Markets
When multiple PE-backed PT groups operate in the same MSA, competition for any single acquisition in that market normalizes. Saturation begins market by market. The MSA-level overlap map often foreshadows the national trend.
⚡
Regulatory Scrutiny Intensifies — A Cross-Sector Accelerant
Across dental, dermatology, ophthalmology, and PE healthcare broadly, increased FTC and DOJ scrutiny has emerged as a factor that slows M&A by lengthening timelines and reducing deal certainty. When regulatory friction increases materially — as it has across multiple specialties in recent years — platforms shift capital toward de novo growth, which faces fewer regulatory hurdles. This dynamic does not make acquisitions impossible, but it does compress the effective window during which premium-priced acquisitions are the preferred strategy.
Mihama Acquisitions · Physical Therapy & Healthcare M&A
The Signal Has Arrived in PT — The Window for Premium Pricing Is Still Open, But Narrowing
The pattern documented in pharmacy, dental, dermatology, and ophthalmology has reached physical therapy. Platform-on-platform acquisitions — the clearest leading indicator of saturation — are already underway. Results, Pivot, Access, Sport and Spine, and Motion have all been absorbed by larger consolidators. That does not mean the market for independent PT practices is closed. It means the clock is running. The independent PT owner who transacts now — while buyer competition among platforms is still active and relationship capital still commands a premium — captures a fundamentally different outcome than the one who waits until the cycle fully matures. Mihama's role is to ensure that when you go to market, you do so at the moment of maximum competitive leverage, with the process and preparation to capture every dollar this market environment will allow.
📞
Speak With an Advisor
347-878-2941
Confidential consultation, no retainer required
🌐
Learn More
www.mihamainc.com
Resources, case studies & transaction experience